source
- Sarepta's Elevidys sales beat forecasts but dip again, prompting stock slide and shift to RNA pipelineSarepta Therapeutics reported that its gene therapy Elevidys generated net product revenue that exceeded Wall Street estimates for the first quarter. However, sales continued to decline compared wi…
- EnGene shares tumble 80% after Phase 2 bladder cancer data raise safety concernsEnGene, a Canadian biotech firm, released updated Phase 2 results for its experimental therapy aimed at a specific group of bladder cancer patients. The company said the new data fell short of expe…